90Y-DOTA-tyr 3 Octreotide with or without Retinoic Acid for the Treatment of Neuroblastoma and Neuroendocrine Tumors in Children and Young Adults: A Randomized, Placebo controlled Phase II Trial with Dosimetry Guided Dosing of 90Y -DOTA-tyr 3 Octreotide (60)

Gender Preference	None
Age Group	0 - 99 years
Research Start Date	June 1, 2009
Research End Date	June 1, 2019
Principal Investigator	M. Sue O'Dorisio, MD
Description	Participants in this study have been diagnosed with neuroblastoma or a neuroendocrine tumor. The purpose of this research study is to assess the safety and effectiveness of the combination of retinoic acid and Onalta® in treating your neuroblastoma or neuroendocrine tumor. Approximately 60 people will take part in this study conducted by investigators at the University of Iowa. Study involvement is life long with treatment lasting approximately 18-24 weeks.
Contact Info	M. Sue O'Dorisio, 319-356-7873
Keywords	span itemProp='description'>cancer ; IRB#200904707 ; neuroblastoma ; neuroendocrine tumor ; o ; onalta® ; pediatric ; phase 2 ; phase II ; retinoic acid ;

Contact